-

Advicenne: 2026 Financial Calendar

PARIS--(BUSINESS WIRE)--Regulatory News:

Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, announces its 2026 financial communication calendar.

Event

Date*

2025 FY sales release

January 22, 2026

2025 FY annual financial statement

March 26, 2026

Annual General Meeting

May 21, 2026

2026 First Half financial statement

September 17, 2026

*: subject to change. End of trading

About Advicenne
Advicenne (Euronext: ALDVI) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal® (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU and GB. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022. For additional information, see: https://advicenne.com/.

Contacts

Advicenne
Didier Laurens, CEO
+33 (0)1 87 44 40 17
Email: investors@advicenne.com

Maarc
Media relations
Bruno Arabian
+33 (0)6 87 88 47 26
Email: bruno.arabian@maarc.fr

Advicenne

BOURSE:ADVIC
Release Versions
EnglishFrench

Contacts

Advicenne
Didier Laurens, CEO
+33 (0)1 87 44 40 17
Email: investors@advicenne.com

Maarc
Media relations
Bruno Arabian
+33 (0)6 87 88 47 26
Email: bruno.arabian@maarc.fr

More News From Advicenne

Advicenne Announces the Opening of a Safeguard Proceedings to Restructure Its Financial Liabilities and Finalize the Extension of Its Cash Runway

PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announces today that the Paris Commercial Court granted its request to initiate a safeguard procedure to restructure its debt within a protective legal framework. As such, the Company’s liabilities incurred prior to the decision are frozen until the end of...

Advicenne 2025 Universal Registration Document Made Available

PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announces today that its 2025 Universal Registration Document has been filed with the French Autorité des Marchés Financiers (AMF). The Universal Registration Document includes the annual report, the management report, the Board of Directors' report on cor...

Advicenne Reports Its 2025 Annual Financial Results

PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announces today its 2025 financial results, and provides an update on its activities. The financial statements for the year 2025 were approved by the Board of Directors at its meeting on March 26, 2026. The audit procedures are being finalized, and the aud...
Back to Newsroom